CHRS — Coherus BioSciences Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Coherus BioSciences Inc

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting inter… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$1.57
Market Cap$245M
Float132.0M
Shares Outstanding154.2M
P/E (Forward)41.15
Price/Sales (TTM)5.23
vs. Analyst Target+396.8% to analyst PT
Profit Margin397.30%
Operating Margin (TTM)-293.67%
Revenue (TTM)$46.9M
Earnings Growth (YoY)-75.50%
Dividend RateNone
Analyst Target Price$7.80 (7 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $476M $132M $438M $162M
2021 $327M -$287M $269M -$261M
2022 $211M -$292M $141M -$256M
2023 $257M -$238M $98.3M -$194M
2024 $267M $28.5M $149M $60.9M
2025 $42.2M -$170M $24.4M -$176M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $10.3M -$41.3M
Sep 2025 $11.6M -$35.1M
Dec 2025 $12.7M -$37.3M
Mar 2026 $12.3M -$37.9M

Ownership & Float

Insider Ownership18.5%
Institutional Ownership33.3%
Short Float21.1%
% of All Funds Holding1.72%
Number of Funds Holding141

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$1.70Near-term / short-term trend
Weekly40-Week SMA$1.56Medium-term trend
Weekly80-Week SMA$1.31Cyclical trend (business cycle)
Weekly200-Week SMA$3.34Secular trend (multi-year)
Monthly10-Month SMA$1.61Near-term monthly trend
Monthly20-Month SMA$1.30Medium-term monthly trend
Monthly40-Month SMA$2.36Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.10 resistance 1.17x 2 months ago
$1.50 support 2.11x 3 months ago

Historical Earnings Reactions (47 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.72% -0.09% 44.68% 14.59% -22.60%
1 Day 0.40% 0.14% 53.19% 30.22% -30.23%
1 Week 1.04% 1.20% 53.19% 37.36% -48.59%
2 Weeks 1.14% 2.46% 58.70% 51.93% -43.98%
1 Month 3.45% -1.38% 47.83% 122.38% -37.29%

Next earnings: May 11, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan4.4%58.3%12
Feb-1.4%41.7%12
Mar0.5%50.0%12
Apr-2.5%58.3%12
May-2.7%45.5%11
Jun-1.8%36.4%11
Jul10.5%54.5%11
Aug11.9%81.8%11
Sep-9.3%18.2%11
Oct-6.2%36.4%11
Nov-0.6%45.5%11
Dec4.1%58.3%12

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.13% 46.9% 542
Tuesday -0.04% 47.1% 596
Wednesday 0.03% 47.2% 593
Thursday -0.21% 44.8% 580
Friday 0.33% 50.4% 581

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 33.3%

Insider Transactions — Smart Summary

Total insider ownership: 18.5%

Founder-led management: Dennis M. Lanfear (President & Chief Executive Officer)

12-Month Insider Activity Summary

Total Filings1
Net Value+N/A
Net Shares Change-99,988
% of Float-0.1%
C-Suite Filings0
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Wahlstrom Mats -$73,881.133 1 1 sell

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-05-28 Wahlstrom Mats -$73,881.133 Transaction at $0.74, now +112.5%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Coherus BioSciences Inc (CHRS) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CHRS on Trend Edge →